These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. Voisset C; Saupe SJ; Galons H; Blondel M Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013 [TBL] [Abstract][Full Text] [Related]
3. Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells. Hamanaka T; Nishizawa K; Sakasegawa Y; Oguma A; Teruya K; Kurahashi H; Hara H; Sakaguchi S; Doh-Ura K J Virol; 2017 Mar; 91(6):. PubMed ID: 28077650 [TBL] [Abstract][Full Text] [Related]
4. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931 [TBL] [Abstract][Full Text] [Related]
5. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Karapetyan YE; Sferrazza GF; Zhou M; Ottenberg G; Spicer T; Chase P; Fallahi M; Hodder P; Weissmann C; Lasmézas CI Proc Natl Acad Sci U S A; 2013 Apr; 110(17):7044-9. PubMed ID: 23576755 [TBL] [Abstract][Full Text] [Related]
6. Discovery of 2-aminothiazoles as potent antiprion compounds. Ghaemmaghami S; May BC; Renslo AR; Prusiner SB J Virol; 2010 Apr; 84(7):3408-12. PubMed ID: 20032192 [TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives. Poli G; Ponti W; Carcassola G; Ceciliani F; Colombo L; Dall'Ara P; Gervasoni M; Giannino ML; Martino PA; Pollera C; Villa S; Salmona M Arzneimittelforschung; 2003; 53(12):875-88. PubMed ID: 14750496 [TBL] [Abstract][Full Text] [Related]
8. New approaches for the selection and evaluation of anti-prion organic compounds. Cordeiro Y; Ferreira NC Mini Rev Med Chem; 2015; 15(2):84-92. PubMed ID: 25723455 [TBL] [Abstract][Full Text] [Related]
9. Continuous quinacrine treatment results in the formation of drug-resistant prions. Ghaemmaghami S; Ahn M; Lessard P; Giles K; Legname G; DeArmond SJ; Prusiner SB PLoS Pathog; 2009 Nov; 5(11):e1000673. PubMed ID: 19956709 [TBL] [Abstract][Full Text] [Related]
10. Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice. Giles K; Berry DB; Condello C; Dugger BN; Li Z; Oehler A; Bhardwaj S; Elepano M; Guan S; Silber BM; Olson SH; Prusiner SB J Pharmacol Exp Ther; 2016 Sep; 358(3):537-47. PubMed ID: 27317802 [TBL] [Abstract][Full Text] [Related]
14. Protein folding activity of the ribosome (PFAR) -- a target for antiprion compounds. Banerjee D; Sanyal S Viruses; 2014 Oct; 6(10):3907-24. PubMed ID: 25341659 [TBL] [Abstract][Full Text] [Related]
15. Vaccine approaches to prevent and treat prion infection : progress and challenges. Müller-Schiffmann A; Korth C BioDrugs; 2008; 22(1):45-52. PubMed ID: 18215090 [TBL] [Abstract][Full Text] [Related]
16. Nanomedicine for prion disease treatment: new insights into the role of dendrimers. McCarthy JM; Appelhans D; Tatzelt J; Rogers MS Prion; 2013; 7(3):198-202. PubMed ID: 23764833 [TBL] [Abstract][Full Text] [Related]
17. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. Gilch S; Winklhofer KF; Groschup MH; Nunziante M; Lucassen R; Spielhaupter C; Muranyi W; Riesner D; Tatzelt J; Schätzl HM EMBO J; 2001 Aug; 20(15):3957-66. PubMed ID: 11483499 [TBL] [Abstract][Full Text] [Related]
18. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. Kawasaki Y; Kawagoe K; Chen CJ; Teruya K; Sakasegawa Y; Doh-ura K J Virol; 2007 Dec; 81(23):12889-98. PubMed ID: 17881452 [TBL] [Abstract][Full Text] [Related]